Education
About Us
Working with TipRanks
Follow Us
iTeos Therapeutics (ITOS)
NASDAQ:ITOS
Total Valuation
iTeos Therapeutics has a market cap or net worth of $215.80M. The enterprise value is -$42.77M.
Market Cap$215.80M
Enterprise Value-$42.77M
Share Statistics
iTeos Therapeutics has 38.19M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38.19M
Owened by Insiders24.52%
Owened by Instutions<0.01%
Financial Efficiency
iTeos Therapeutics’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -27.50%.
Return on Equity (ROE)-22.77%
Return on Assets (ROA)-19.57%
Return on Invested Capital (ROIC)-27.50%
Return on Capital Employed (ROCE)-24.67%
Revenue Per Employee$202,312.139
Profits Per Employee-$776,959.538
Employee Count173
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of iTeos Therapeutics is -2.31. iTeos Therapeutics’s PEG ratio is -0.43.
PE Ratio-2.31
PS Ratio8.88
PB Ratio0.53
Price to Fair Value0.53
Price to FCF-3.11
Price to Operating Cash Flow-3.17
PEG Ratio-0.43
Income Statement
In the last 12 months, iTeos Therapeutics had revenue of $35.00M and earned -$134.41M in profits. Earnings per share was -$3.38.
Revenue$35.00M
Gross Profit$34.39M
Operating Income-$159.53M
Pretax Income-$122.04M
Net Income-$134.41M
EBITDA-155.14M
Earnings Per Share (EPS)-3.38
Cash Flow
In the last 12 months, operating cash flow was -$98.18M and capital expenditures -$1.63M, giving a free cash flow of -$99.81M billion.
Operating Cash Flow-$98.18M
Free Cash Flow-$99.81M
Free Cash Flow per Share-$2.61
Dividends & Yields
iTeos Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-32.11%
Earnings Yield-43.24%
Stock Price Statistics
Beta1.57
52-Week Price Change-51.96%
50-Day Moving Average6.83
200-Day Moving Average10.31
Relative Strength Index (RSI)25.94
Average Volume (3m)371.11K
Important Dates
iTeos Therapeutics upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 5, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
iTeos Therapeutics as a current ratio of 12.62, with Debt / Equity ratio of <0.01
Current Ratio12.62
Quick Ratio12.62
Debt to Market Cap0.02
Net Debt to EBITDA0.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, iTeos Therapeutics has paid $12.38M in taxes.
Income Tax$12.38M
Effective Tax Rate-11.69%
Enterprise Valuation
iTeos Therapeutics EV to EBITDA ratio is -1.14, with an EV/FCF ratio of -1.74.
EV to Sales4.97
EV to EBITDA-1.14
EV to Free Cash Flow-1.74
EV to Operating Cash Flow-1.77
Balance Sheet
iTeos Therapeutics has $494.65M in cash and marketable securities with $5.10M in debt, giving a net cash position of -$489.55M billion.
Cash & Marketable Securities$494.65M
Total Debt$5.10M
Net Cash-$489.55M
Net Cash Per Share-$12.82
Tangible Book Value Per Share$14.58
Margins
Gross margin is 100.00%, with operating margin of -455.79%, and net profit margin of -384.04%.
Gross Margin100.00%
Operating Margin-455.79%
Pretax Margin-343.83%
Net Profit Margin-384.04%
EBITDA Margin-437.39%
EBIT Margin-440.93%
Analyst Forecast
The average price target for iTeos Therapeutics is $23.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.20
Price Target Upside310.62%
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast177.89%
EPS Growth Forecast-10.95%